Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer
Condition(s) studied
Investigational drug(s) / intervention(s)
Palbociclib 125mg: Palbociclib 125 mg oral tablet taken daily for 3 years from randomization
Standard endocrine therapy: Aromatase inhibitor (anastrozole or exemestane or letrozole) oral daily tablet, or Selective Estrogen Receptor Modulator (SERM) such as tamoxifen oral daily tablet or fulvestrant (Faslodex) injection once every 2 weeks for 3 doses then every month. Premenopausal women and men may also receive an LHRH (luteinizing hormone-releasing hormone) agonist by injection. Standard endocrine therapy will be given for at least 3 years from randomization.
Study summary
POLAR is a phase III clinical trial, which will test the safety and efficacy of an investigational combination of drugs to learn whether the combination of drugs works for a specific cancer. Palbociclib (Ibrance®) is the name of the investigational agent, which is assessed together with standard anti-hormone therapy in this study. Palbociclib is used to treat patients with hormone receptor-positive / HER2-negative breast cancer which has spread beyond the original tumor and/or to other organs.
During this study, anti-hormone therapy will consist of either a selective estrogen receptor modulator (such as tamoxifen) or an aromatase inhibitor (anastrozole, letrozole, exemestane) or fulvestrant (Faslodex®). Premenopausal women and men may also receive a drug called an LHRH (luteinizing hormone-releasing hormone) agonist by injection.
It is standard of care for people with hormone receptor positive breast cancer to take anti-hormone therapy. The study doctor will determine the type of standard anti-hormone therapy that will be given during this trial.
The purpose of the POLAR study is to compare the effect of using 3 years of palbociclib in combination with standard anti-hormone therapy with standard anti-hormone therapy alone and to evaluate the time until the breast cancer returns, if it does return.
Eligibility
Primary outcome measure(s)
- Duration of invasive disease free survival of all randomized participants. — Assessed from the date treatment starts until the date of first documented invasive local, regional or distant recurrence, a second invasive cancer or death, or until approximately 4 years after treatment stops.
Defined as the time from randomization until first appearance of invasive local, regional or distant recurrence (including invasive ipsilateral breast tumour recurrence), invasive contralateral breast cancer, a second (non-breast) invasive cancer, or death from any cause. The sites of first invasive disease events will be compared between treatment groups using a stratified log-rank test and will be tabulated.
Trial sites (53)
| Facility | City | Region | Status |
|---|---|---|---|
| Medizinische Universität Graz (MUG) | Graz | Austria | |
| Medizinische Universität Innsbruck - Univ.-Klinik f. Frauenheilkunde | Innsbruck | Austria | |
| Uniklinikum Salzburg | Salzburg | Austria | |
| MUW - Universitätsklinik für Innere Medizin | Vienna | Austria | |
| Institut Sainte Catherine | Avignon | France | |
| Institut Bergonie | Bordeaux | France | |
| Polyclinique Bordeaux Nord | Bordeaux | France | |
| Centre Francois Baclesse | Caen | France | |
| Cêntre Hospitaler de Cholet | Cholet | France | |
| Centre Georges François Leclerc | Dijon | France | |
| Centre Hospitalier Universitaire de Limoges | Limoges | France | |
| Groupe hospitalier de Bretagne Sud, Hôpital du Scorff | Lorient | France | |
| Centre Leon Berard | Lyon | France | |
| ICM Val d'Aurelle | Montpellier | France | |
| Centre Antoine Lacassagne | Nice | France | |
| Centre Paul Strauss | Strasbourg | France | |
| Institut Claudius Regaud | Toulouse | France | |
| Gustave Roussy | Villejuif | France | |
| National Institute of Oncology | Budapest | Hungary | |
| Cro Irccs | Aviano | Italy | |
| ASST Papa Giovanni XXIII | Bergamo | Italy | |
| PO Antonio Perrino Brindisi | Brindisi | Italy | |
| Istituto scientifico Romagnolo per lo studio e la cura | Meldola | Italy | |
| Istituto Europeo di Oncologia | Milan | Italy | |
| AOU Maggiore Della Carita, University of Eastern Piedmont | Novara | Italy | |
| Azienda Ospedaliero-Universitaria di Parma | Parma | Italy | |
| Istituti Clinici Scientifici Maugeri | Pavia | Italy | |
| Ospedale S. Stefano | Prato | Italy | |
| U.O. Oncologia, Ospedale Infermi | Rimini | Italy | |
| Hospital Universitario de Canarias | San Cristóbal de La Laguna | Tenerife | |
| Hospital Universitario de La Coruña | A Coruña | Spain | |
| Hospital General Universitario de Alicante | Alicante | Spain | |
| Hospital Universitario Vall d´Hebrón | Barcelona | Spain | |
| Instituto Catalan de Oncologia L´Hospitalet | Barcelona | Spain | |
| Hospital de Basurto | Bilbao | Spain | |
| Institut Català d´Oncología (ICO) | Girona | Spain | |
| Hospital Universitario 12 de Octubre | Madrid | Spain | |
| HU Ramón y Cajal | Madrid | Spain | |
| Hospital Virgen de la Victoria | Málaga | Spain | |
| Hospital Virgen de la Macarena | Seville | Spain |
+ 13 more sites — see the full list on the official registry below.
More ETOP IBCSG Partners Foundation trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT03820830 on ClinicalTrials.gov ↗ ← All trials in France